{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:11:22Z","timestamp":1777990282709,"version":"3.51.4"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The objective of this study was to conduct a systematic review and network meta-analysis (NMA) to compare the efficacy of various anti-osteoporosis drugs in preventing femoral periprosthetic bone loss following total hip arthroplasty (THA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Randomized controlled trials (RCTs) assessing the clinical efficacy of various anti-osteoporosis drugs and control treatments in preventing periprosthetic bone loss following THA were identified. Outcomes evaluated included bone mineral density (BMD) at 6\u00a0months, 12\u00a0months, 24\u00a0months, and 5\u201310\u00a0years. The network meta-analysis was conducted using Stata 13.0 and R-3.5.1 software with the \u201cgemtc\u201d package.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 33 RCTs with 1,169 patients were included. At 6\u00a0months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, raloxifene, teriparatide + alendronate, and zoledronic acid were beneficial in increasing BMD, with denosumab ranking highest (based on surface under the cumulative ranking curve (SUCRA) values). At 12\u00a0months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, risedronate, and zoledronic acid showed benefits, with alendronate + alfacalcidol ranking highest (SUCRA = 0.97). For 24-month BMD, teriparatide + alendronate ranked highest (SUCRA = 0.82). Analysis of BMD at 5\u201310\u00a0years, involving four studies on alendronate, pamidronate, and placebo, indicated that alendronate achieved the highest SUCRA value (0.87).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both denosumab and bisphosphonates are effective in preventing femoral periprosthetic bone loss following THA. Denosumab was the most efficient agent for increasing BMD at 6\u00a0months post-THA, while alendronate combined with alfacalcidol or feriparatide was most efficient at 12\u00a0months and 24\u00a0months. More high-quality direct comparisons and long-term follow-up studies are needed to determine the optimal drug and dosage for THA patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1566890","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:07Z","timestamp":1764225007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhi-Hu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14712598.2025.2540471","article-title":"Biosimilars in osteoporosis treatment: focus on denosumab","volume":"25","author":"Aapro","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4097\/kja.21358","article-title":"Concepts and emerging issues of network meta-analysis","volume":"74","author":"Ahn","year":"2021","journal-title":"Korean J. Anesthesiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.arth.2022.01.077","article-title":"Bone preservation in total hip arthroplasty","volume":"37","author":"Anderl","year":"2022","journal-title":"J. Arthroplasty"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/jor.20162","article-title":"Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study","volume":"24","author":"Arabmotlagh","year":"2006","journal-title":"J. Orthop. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/jor.20748","article-title":"Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty","volume":"27","author":"Arabmotlagh","year":"2009","journal-title":"J. Orthop. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/145749691210100405","article-title":"Salmon calcitonin (miacalcic ns 200 IU) in prevention of bone loss after hip replacement","volume":"101","author":"Arnala","year":"2012","journal-title":"Scand. J. Surg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jbiomech.2018.04.041","article-title":"A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: a randomized placebo-controlled trial of women undergoing total hip arthroplasty","volume":"75","author":"Aro","year":"2018","journal-title":"J. Biomech."},{"key":"B8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2106\/jbjs.d.01772","article-title":"Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis","volume":"87","author":"Bhandari","year":"2005","journal-title":"J. Bone Jt. Surg. Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","article-title":"Denosumab: a review in postmenopausal osteoporosis","volume":"35","author":"Deeks","year":"2018","journal-title":"Drugs Aging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/biomedicines12081778","article-title":"Efficacy of bisphosphonates in total hip arthroplasty patients: systematic review and meta-analysis","volume":"12","author":"Di Martino","year":"2024","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1336075","DOI":"10.3389\/fphar.2024.1336075","article-title":"Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis","volume":"15","author":"Dong","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jrsm.1195","article-title":"GetReal in network meta-analysis: a review of the methodology","volume":"7","author":"Efthimiou","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"B14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00264-005-0018-2","article-title":"Etidronate does not suppress periprosthetic bone loss following cemented hip arthroplasty","volume":"29","author":"Fokter","year":"2005","journal-title":"Int. Orthop."},{"key":"B15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijsu.2017.08.559","article-title":"Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: a meta-analysis from randomized controlled trails","volume":"47","author":"Gao","year":"2017","journal-title":"Int. J. Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/1120700018808023","article-title":"Changes in periacetabular bone mineral density five years after resurfacing hip arthroplasty versus conventional total hip arthroplasty","volume":"29","author":"Gerhardt","year":"2019","journal-title":"Hip Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/os.12696","article-title":"Raloxifene prevents early periprosthetic bone loss for postmenopausal women after uncemented total hip arthroplasty: a randomized placebo-controlled clinical trial","volume":"12","author":"Gong","year":"2020","journal-title":"Orthop. Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jos.2024.01.011","article-title":"Anti-osteoporotic drug efficacy for periprosthetic bone loss after total hip arthroplasty: a systematic review and network meta-analysis","volume":"30","author":"Hatano","year":"2025","journal-title":"J. Orthop. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/s-2002-22090","article-title":"Dose-dependent prevention of early periprosthetic bone loss by alendronate","volume":"140","author":"Hennigs","year":"2002","journal-title":"Z Orthop. Ihre Grenzgeb"},{"key":"B20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12891-017-1577-2","article-title":"Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial","volume":"18","author":"Huang","year":"2017","journal-title":"BMC Musculoskelet. Disord."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2106\/jbjs.i.01714","article-title":"A comparison of the effects of alendronate and alfacalcidol on bone mineral density around the femoral implant and in the lumbar spine after total hip arthroplasty","volume":"93","author":"Iwamoto","year":"2011","journal-title":"J. Bone Jt. Surg. Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00774-013-0526-x","article-title":"The effectiveness of mono or combined osteoporosis drug therapy against bone mineral density loss around femoral implants after total hip arthroplasty","volume":"32","author":"Iwamoto","year":"2014","journal-title":"J. Bone Min. Metab."},{"key":"B25","first-page":"44","article-title":"Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study","volume":"72","author":"Kinov","year":"2006","journal-title":"Acta Orthop. Belg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5301\/hipint.5000413","article-title":"Periprosthetic femoral bone loss in total hip arthroplasty: systematic analysis of the effect of stem design","volume":"27","author":"Knutsen","year":"2017","journal-title":"Hip Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.arth.2015.07.017","article-title":"Teriparatide Versus alendronate for the preservation of bone mineral density after total hip arthroplasty - a randomized controlled trial","volume":"31","author":"Kobayashi","year":"2016","journal-title":"J. Arthroplasty"},{"key":"B28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/17453674.2017.1300746","article-title":"Denosumab reduces early migration in total knee replacement","volume":"88","author":"Ledin","year":"2017","journal-title":"Acta Orthop."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00198-011-1797-5","article-title":"Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials","volume":"23","author":"Lin","year":"2012","journal-title":"Osteoporos. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0243851","DOI":"10.1371\/journal.pone.0243851","article-title":"Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: a network meta-analysis of randomized controlled trials","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","article-title":"Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis","volume":"16","author":"Migliorini","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"117392","DOI":"10.1016\/j.bone.2025.117392","article-title":"Real-world safety and effectiveness of romosozumab following daily or weekly administration of teriparatide in primary and secondary osteoporosis","volume":"193","author":"Mineta","year":"2025","journal-title":"Bone"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13018-020-1547-5","article-title":"Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial","volume":"15","author":"Morita","year":"2020","journal-title":"J. Orthop. Surg. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3109\/17453674.2015.1041846","article-title":"No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial","volume":"86","author":"Muren","year":"2015","journal-title":"Acta Orthop."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00590-018-2223-x","article-title":"Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty","volume":"28","author":"Nagoya","year":"2018","journal-title":"Eur. J. Orthop. Surg. Traumatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"17021","DOI":"10.1038\/boneres.2017.21","article-title":"Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment","volume":"5","author":"Nakamura","year":"2017","journal-title":"Bone Res."},{"key":"B37","first-page":"593","article-title":"Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study","volume":"89","author":"Nehme","year":"2003","journal-title":"Rev. Chir. Orthop. Reparatrice Appar. Mot."},{"key":"B38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00774-006-0743-7","article-title":"Alendronate inhibits periprosthetic bone loss around uncemented femoral components","volume":"25","author":"Nishioka","year":"2007","journal-title":"J. Bone Min. Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/jbmr.3883","article-title":"Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a randomized placebo-controlled clinical trial","volume":"35","author":"Nystr\u00f6m","year":"2020","journal-title":"J. Bone Min. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e45662","DOI":"10.7759\/cureus.45662","article-title":"Effects of teriparatide treatment on bone mineral density in patients with osteoporosis: a short-term dose-response study","volume":"15","author":"Roy","year":"2023","journal-title":"Cureus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00264-020-04683-x","article-title":"Pre-operative bone mineral density is a predictive factor for excellent early patient-reported outcome measures in cementless total hip arthroplasty using a proximally fixed anatomic stem. A prospective study at two year minimum follow-up","volume":"44","author":"Sariali","year":"2020","journal-title":"Int. Orthop."},{"key":"B43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.arth.2012.08.007","article-title":"Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial","volume":"28","author":"Scott","year":"2013","journal-title":"J. Arthroplasty"},{"key":"B44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med. Res. Methodol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1302\/0301-620x.88b10.17308","article-title":"Clinical and radiological outcome of total hip replacement five years after pamidronate therapy. A trial extension","volume":"88","author":"Shetty","year":"2006","journal-title":"J. Bone Jt. Surg. Br."},{"key":"B46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12891-018-2101-z","article-title":"Effect of bisphosphonates on periprosthetic bone loss after total knee arthroplasty: a meta-analysis of randomized controlled trials","volume":"19","author":"Shi","year":"","journal-title":"BMC Musculoskelet. Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00198-018-4488-7","article-title":"Bisphosphonates for the preservation of periprosthetic bone mineral density after total joint arthroplasty: a meta-analysis of 25 randomized controlled trials","volume":"29","author":"Shi","year":"","journal-title":"Osteoporos. Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol. Health"},{"key":"B49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/jmh.jmh_108_25","article-title":"Comparison of efficacy and safety of romosozumab versus denosumab for treatment of postmenopausal osteoporosis: a meta-analysis","volume":"16","author":"Singh","year":"2025","journal-title":"J. Midlife Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2106\/jbjs.j.01646","article-title":"The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial","volume":"93","author":"Skoldenberg","year":"2011","journal-title":"J. Bone Jt. Surg. Am."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/os.12984","article-title":"Early rehabilitation and periprosthetic bone environment after primary total hip arthroplasty: a randomized controlled trial","volume":"13","author":"Su","year":"2021","journal-title":"Orthop. Surg."},{"key":"B52","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/14397595.2017.1308454","article-title":"Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis","volume":"28","author":"Suzuki","year":"","journal-title":"Mod. Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/nu10030272","article-title":"Vitamin D and calcium addition during denosumab therapy over a period of four years significantly improves lumbar bone mineral density in Japanese osteoporosis patients","volume":"10","author":"Suzuki","year":"","journal-title":"Nutrients"},{"key":"B54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/145749691009900108","article-title":"Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty - a 5-year follow-up of 16 patients","volume":"99","author":"Tapaninen","year":"2010","journal-title":"Scand. J. Surg."},{"key":"B55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/145749691210100312","article-title":"Femoral neck bone mineral density after resurfacing hip arthroplasty","volume":"101","author":"Tapaninen","year":"2012","journal-title":"Scand. J. Surg."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1016\/j.arth.2016.04.023","article-title":"Periprosthetic bone remodeling after novel short-stem neck-sparing total hip arthroplasty","volume":"31","author":"Tran","year":"2016","journal-title":"J. Arthroplasty"},{"key":"B57","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00223-010-9356-1","article-title":"Decreased periprosthetic bone loss in patients treated with clodronate: a 1-year randomized controlled study","volume":"86","author":"Trevisan","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1359\/jbmr.2001.16.11.2126","article-title":"Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study","volume":"16","author":"Venesmaa","year":"2001","journal-title":"J. Bone Min. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijsu.2018.02.007","article-title":"Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty: a systematic review and meta-analysis","volume":"52","author":"Wang","year":"2018","journal-title":"Int. J. Surg."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.orthres.2004.06.004","article-title":"Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial","volume":"23","author":"Wilkinson","year":"2005","journal-title":"J. Orthop. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/s8756-3282(03)00085-1","article-title":"Cyclic therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty","volume":"33","author":"Yamaguchi","year":"2003","journal-title":"Bone"},{"key":"B63","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bone.2004.03.017","article-title":"Effects of discontinuation as well as intervention of cyclic therapy with etidronate on bone remodeling after cementless total hip arthroplasty","volume":"35","author":"Yamaguchi","year":"2004","journal-title":"Bone"},{"key":"B64","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00776-004-0854-8","article-title":"Efficacy of different dosing schedules of etidronate for stress shielding after cementless total hip arthroplasty","volume":"10","author":"Yamaguchi","year":"2005","journal-title":"J. Orthop. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00198-007-0339-7","article-title":"Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty","volume":"18","author":"Yamasaki","year":"2007","journal-title":"Osteoporos. Int."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e8806","DOI":"10.1097\/md.0000000000008806","article-title":"Periprosthetic bone remodeling of short cementless femoral stems in primary total hip arthroplasty: a systematic review and meta-analysis of randomized-controlled trials","volume":"96","author":"Yan","year":"2017","journal-title":"Med. Baltim."},{"key":"B67","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s1473-3099(19)30301-9","article-title":"Preventive effect of ibandronate on bone loss around prosthesis stem after hip replacement","volume":"21","author":"Yang","year":"2019","journal-title":"J. Trauma. Surg."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.arth.2017.02.036","article-title":"Efficacy of alendronate for the prevention of bone loss in calcar region following total hip arthroplasty","volume":"32","author":"Yukizawa","year":"2017","journal-title":"J. Arthroplasty"},{"key":"B69","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00264-017-3551-x","article-title":"The effect of simvastatin on periprosthetic bone mineral density in the hypercholesterolaemic patients after total hip arthroplasty","volume":"42","author":"Zhang","year":"2018","journal-title":"Int. Orthop."},{"key":"B70","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13018-015-0206-8","article-title":"Effect of bisphosphonates in preventing femoral periprosthetic bone resorption after primary cementless total hip arthroplasty: a meta-analysis","volume":"10","author":"Zhao","year":"2015","journal-title":"J. Orthop. Surg. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00198-019-05005-7","article-title":"Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis","volume":"30","author":"Zhou","year":"2019","journal-title":"Osteoporos. Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1566890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:08Z","timestamp":1764225008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1566890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":71,"alternative-id":["10.3389\/fphar.2025.1566890"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1566890","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1566890"}}